SubHero Banner
Text

Leukine® (sargramostim) – New indication, safety updates

March 29, 2018 - The FDA announced the approval of Partner Therapeutics’ Leukine (sargramostim) to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

Download PDF